Drug intelligence / Profile preview

G2602

Development stage: Preclinical
Lead developer: BCWorld Pharma
Modality: Small Molecules
Administration: Oral

Overview

G2602 is a small molecule therapeutic candidate being developed by BCWorld Pharma for the treatment of kidney disease. It is formulated as an orally disintegrating tablet (ODT) using the company's proprietary drug delivery technology. As of 2024, the program is in the preclinical formulation research stage. The specific active pharmaceutical ingredient has not been publicly disclosed, but the ODT format is intended to improve patient compliance and ease of administration, particularly for patients with fluid restrictions or swallowing difficulties common in chronic kidney disease.

Beyond the preview

Go deeper on G2602.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G2602.

Explore the full profile